In this ERN Rare-Liver webinar, held on 8 March 2022, Thomas Reiberger and Lukas Burghart presented data on the non-invasive diagnosis of CSPH in PBC, and on the impact of CSPH in PBC. Since most guidelines were based on data from CSPH occuring in patients with common liver diseases, he also underlined the diagnostic difficulties and the special consideration in rare liver diseases for the management of CSPH.

Targeted Audience

  • General practitioners
  • Hepatologists
  • Oncologists
  • Health care professionals

Management of Portal Hypertension (CSPH) in PBC


Lukas Burghart Lukas Burghart is a GI resident at the Vienna-Ottakring municipal hospital associated with the Medical University of Vienna, where he is inscribed in the clinical PhD program. Dr. Burghart is part of the research group of Prof. Thomas Reiberger, and his PhD projects focus on the development of portal hypertension and the prognostic impact of clinically significant portal hypertension in patients with rare liver diseases. Importantly, Lukas Burghart has recently described the course of portal hypertension and the prognostic implications of its distinct clinical features in primary biliary cholangitis (PBC).
Thomas Reiberger Thomas Reiberger coordinates the Vienna Rare Liver Disease (RALID) center at the Vienna General Hospital, an affiliated member of the European Reference Network (ERN RARE LIVER). As a Professor of Hepatology he is heading the Liver Outpatient Clinic and runs a Laboratory for Portal Hypertension and Liver Fibrosis at the Medical University of Vienna. His translational research focuses on hemodynamic and structural characteristics of advanced chronic liver disease as well as diagnostic and prognostic biomarkers and extends to patients with rare liver diseases.
Log in to post comments